Therapeutic Overview of Pitophenone Hydrochloride

Pitophenone hydrochloride is a pharmaceutical agent administered to manage symptoms associated with the contraction of smooth muscles within the body's internal organs. Its primary use is to relieve the painful spasm that occurs in conditions affecting the gastrointestinal, urinary, and biliary tracts.

This agent is frequently used as a component in a fixed-dose combination product, often alongside other compounds that support pain relief and muscle relaxation to address various forms of colic, such as renal, ureteric, intestinal, or biliary colic. The therapeutic benefit is centered on its ability to help resolve the involuntary muscle contraction, which is a direct source of discomfort and pain in these clinical presentations.

Pitophenone hydrochloride is an antispasmodic agent primarily used to relieve pain associated with smooth muscle spasms in conditions affecting the gastrointestinal and urinary tracts. Its use is determined by a patient's underlying health conditions and history of drug sensitivities.

While generally used for its muscle-relaxing effects, it is contraindicated and should not be used in individuals with certain severe health issues or sensitivities. Patients with a known allergy or hypersensitivity to pitophenone or its combination components must avoid the drug. Specific medical conditions that typically prevent its use include:

Contraindication Category	Examples of Conditions
Cardiovascular	Tachyarrhythmias (abnormally fast heart rhythms), unstable circulatory conditions
Gastrointestinal/Urogenital	Obstructive conditions (e.g., prostatic hypertrophy, intestinal obstruction), renal porphyria
Ocular	Narrow-angle glaucoma
Blood/Immune	Certain conditions like glucose-6-phosphate dehydrogenase (G6PD) deficiency, or a history of drug-induced agranulocytosis (especially if combined with Metamizole)

Use in infants and small children requires extra caution and is often done under close medical supervision. Furthermore, due to its potential to damage fertility or the unborn child (in animal studies), it should generally be avoided during pregnancy and breastfeeding, unless the treating physician determines the benefit outweighs the risks.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of pitophenone hydrochloride largely through its use in fixed-dose combination products that also contain fenpiverinium bromide and metamizole sodium. The stated interactions primarily reflect the constraints associated with these co-administered agents.

Documented Interacting Categories

Interacting Medicinal Product Category	Practical Regulatory Constraint
Cholinolytic agents (due to Fenpiverinium)	May lead to an increased risk of side effects due to an enhanced cholinolytic effect; caution or avoidance is required.
Tricyclic Antidepressants, Sympathomimetics	Use is constrained due to the potential for additive pharmacological effects from the combination product components.
Analgesics / Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Concomitant use with other analgesic or antirheumatic drugs requires medical consultation to manage potential risks and cumulative exposure.

Specific Regulatory Constraints

The overall interaction structure imposes constraints related to vulnerable populations; the use of combined preparations containing Pitophenone and Metamizole/Fenpiverinium requires specific caution and medical consultation for children and adolescents under 18 years of age when other analgesic or antirheumatic drugs are also being used. The resulting profile defines several combinations as requiring special circumstances for use or outright avoidance, focusing on preventing the accumulation of anticholinergic and analgesic effects. The preparation is generally restricted to short-term treatment where other therapeutic options are unsuitable.

Dual Musculotropic and Neurotropic Action

Pitofenone exerts a dual-mechanism action on smooth muscle tone via nerve signal modulation and direct muscle cell interaction. The mechanism involves competitive antagonism at peripheral muscarinic receptors (neurotropic), simultaneously combined with direct modulation of the muscle's contraction machinery (musculotropic).

---

Modulating Intracellular Contraction Cascades

Pitofenone's direct, musculotropic effect modulates the flow of calcium ions (Ca^2+) and inhibits specific Phosphodiesterase (PDE) enzymes inside the smooth muscle cell. By raising the levels of key second messengers (cAMP/cGMP), the mechanism disrupts the molecular cascade that causes muscle fibers to shorten, resulting in smooth muscle relaxation and a reduction in visceral muscle tone.

---

Functional Synergy in Combination Formulas

Pitofenone is often formulated with an analgesic, creating a functional synergy where the two active ingredients modulate distinct mechanistic pathways involved in hypercontractile physiological states. Pitofenone modulates the underlying spasm (the mechanical cause) through its dual mechanism, while the analgesic component modulates nociception (sensory signaling). The coordination of these mechanisms achieves robust modulation of the hypercontractile state.

How to Use Pitophenone Hydrochloride: Official Administration Guidelines

Pitophenone hydrochloride is primarily used in fixed-dose combination products as a smooth muscle relaxant. Official usage instructions are strictly defined by established product guidelines and must be followed precisely. This information is descriptive and not therapeutic advice.

---

Official Dosage Forms and Routes

Usage Entity	Official, Label-Based Information
Dosage Forms	Tablets (film-coated) for oral use, and Solution for Injection (ampoules) for parenteral use.
Routes of Administration	Oral, Intravenous (IV) injection, and Intramuscular (IM) injection.

---

Standard Dosing and Administration Protocol

Administration is typically restricted to short-term use only and is often on an as-needed basis for acute conditions, not for prolonged chronic treatment. The specific dose (mg or mL volume) and the maximum number of times it can be taken daily (e.g., up to three times per day) are strictly specified in the product labeling.

Key procedural instructions include:

• Oral Use: Tablets should generally be swallowed whole with water, typically without specific timing constraints regarding meals.
• Parenteral Use: The injection is reserved for acute situations or when the oral route is not feasible. Intravenous administration must be performed slowly, often over 3 to 5 minutes, and the patient may require monitoring during the procedure. Dose adjustments may be necessary for pediatric patients or those with existing hepatic or renal impairment, as explicitly stated in the prescribing information.

Evidence for Use in Acute Colic and Smooth Muscle Spasm

Research involving Pitophenone hydrochloride was studied for conditions characterized by fluctuating or episodic manifestations of acute colic and muscle spasm. This medicine was evaluated in clinical trials primarily as a component within a fixed-dose combination product that includes an analgesic (a pain reliever).

These clinical trials, often designed as randomized controlled trials (RCTs), studies monitored the combination’s use in adult patients presenting with acute symptoms, such as those related to kidney or ureteric colic. The studies explored outcomes related to physical discomfort during these episodes of heightened symptom activity.

---

Study Design, Outcomes, and Limitations

The study designs were generally focused on research exploring short-term symptom changes in patients. Researchers used in research exploring how symptoms change over time, monitoring patient-reported change in pain intensity and observing how frequently patients required rescue medication. The findings describe patterns observed in the studies related to pain intensity measurements. These studies represent a Moderate level of certainty for the fixed-dose combination.

The evidence collected mainly stems from research exploring short-term symptom changes. Follow-up durations were limited in the major clinical trials; thus, there is limited information for long-term outcomes regarding continued use. Furthermore, data for certain groups remain insufficient. Evidence is limited for specific patient subgroups such as older adults, and the results apply only to the populations studied.

A key limitation is that studies have primarily explored its use as a component in a fixed-dose combination product. Consequently, the evidence regarding the clinical profile of Pitophenone hydrochloride as a single agent is not fully established. The research so far highlights what is known — and what is still uncertain.

Key Studies & References NIH MeSH Therapeutic Overview: Pitofenone Hydrochloride and Combination Products

Common questions about Pitophenone hydrochloride (FAQ)

Q: What is Pitophenone hydrochloride used to treat?

Official product information states that this medicine is indicated for the relief of smooth muscle spasms and associated pain. It has been evaluated in conditions such as acute kidney or ureteric colic. Its administration is generally restricted to short-term treatment.

Q: Can I take Pitophenone hydrochloride with food?

Regulatory information indicates that oral tablets are typically swallowed whole with water. Administration is generally performed without specific constraints regarding the timing of meals. Detailed guidance can be found in the full prescribing information for the specific product.

Q: Does Pitophenone hydrochloride interact with other medicines I take?

Yes, official documents indicate that this medicine may have interactions with specific categories of drugs, including cholinolytic agents, tricyclic antidepressants, and some analgesics. Regulatory constraints highlight the importance of reviewing all concurrent medications with a healthcare provider to manage potential risks.

Q: Can Pitophenone hydrochloride be used for children?

According to official information, use in infants and small children should be under close medical supervision due to the need for extra caution. Furthermore, the product is restricted or contraindicated for children under 18 years of age when used concomitantly (at the same time) with other analgesic or anti-rheumatic drugs.

Q: What should I do if I miss a dose of Pitophenone hydrochloride?

Instructions for managing a single missed dose are often not explicitly detailed on the primary patient-facing label. Patients are typically directed to consult a prescribing physician or a pharmacist for specific guidance on how to manage a missed dose.

Q: Is Pitophenone hydrochloride habit-forming?

Official product information focuses on classifying potential adverse reactions and clinical concerns. Dependency or habit-forming potential is generally not listed as a reported adverse reaction or clinical concern for this specific class of drug.

How to Store and Dispose of Pitophenone Hydrochloride

Official storage and disposal instructions for Pitophenone hydrochloride follow general regulatory requirements for medicinal products, as a specific, public patient label from the FDA or EMA is not available. Storage conditions are defined to maintain stability and prevent degradation.

Storage Requirement	Official Regulatory Statement
Child Safety	Must be kept out of the sight and reach of children [NIH MedlinePlus].
Environmental Protection	Store the container tightly closed to protect it from moisture and direct sunlight [General Regulatory Principle].
Disposal	Unused or expired product must be disposed of in accordance with local regulations and must not be thrown away via wastewater or household waste [FDA Disposal Guidance].

The medicine should be stored in its original container and away from excessive heat. Disposal is strictly managed to prevent environmental contamination, mandating the use of approved local drug take-back programs.